SPEG

SPEG Full Name

SPEG complex locus

SPEG Introduction

SPEG (striated muscle preferentially expressed protein kinase, also known as aortic preferentially expressed protein 1 or APEG-1) is a large serine/threonine protein kinase belonging to the myosin light chain kinase family. The gene is located on chromosome 2q35 and spans approximately 59 kb, encoding a protein of 3,267 amino acids with a molecular weight of approximately 354 kDa. SPEG is predominantly expressed in striated muscle tissues including cardiac and skeletal muscle, as well as in aortic vascular smooth muscle cells, where it plays critical roles in myocyte cytoskeletal development, excitation-contraction coupling, and calcium homeostasis. The protein contains two serine/threonine protein kinase domains (SK1 and SK2) and multiple immunoglobulin-like and fibronectin type III repeats that mediate protein-protein interactions. Four major isoforms of SPEG have been identified: SPEG-alpha and SPEG-beta are expressed in striated muscle, while APEG-1 is expressed in aortic smooth muscle cells and BPEG is potentially expressed in aorta and brain. SPEG has emerged as a critical regulator of cardiac and skeletal muscle function, and mutations in this gene are associated with centronuclear myopathy (CNM) with or without dilated cardiomyopathy (DCM), as well as with isolated cardiomyopathy and atrial fibrillation.

Figure 1. Schematic structure of SPEG.

Biological Functions in Muscle Development and Calcium Homeostasis
SPEG plays essential roles in muscle development, regeneration, and excitation-contraction coupling through its kinase activities. The two kinase domains of SPEG, SK1 and SK2, phosphorylate distinct but complementary sets of substrates that are critical for normal cardiac and skeletal muscle function. The SK1 domain phosphorylates junctophilin-2 (JPH2), a protein that anchors the sarcoplasmic reticulum to the transverse tubule system, thereby maintaining proper excitation-contraction coupling. The SK2 domain phosphorylates sarco-endoplasmic reticulum calcium ATPase 2a (SERCA2a), which actively transports calcium ions from the cytosol into the sarcoplasmic reticulum for storage, thereby regulating calcium reuptake and cardiomyocyte relaxation. Beyond its direct kinase activities, SPEG forms a tripartite structure with the sarcoplasmic reticulum and transverse tubules, actively moving calcium ions into the sarcoplasmic reticulum for storage. SPEG is also highly expressed in the mitochondria of muscle cells, where it helps maintain mitochondrial cristae structure and ATP production rates. In addition, SPEG interacts with myotubularin (MTM1), the protein product of the gene mutated in X-linked myotubular myopathy, and this interaction is essential for proper excitation-contraction coupling and cytoskeletal organization in skeletal muscle.

Role in Atrial Fibrillation and Emerging Therapeutic Implications
Beyond its established role in inherited cardiomyopathy and myopathy, SPEG has recently been implicated in the pathogenesis of atrial fibrillation (AF), the most common cardiac arrhythmia. SPEG expression is significantly different between AF patients and individuals in normal sinus rhythm, and ROC curve analysis indicates that SPEG expression has high accuracy (area under the curve >0.92) in predicting AF risk. The mechanism linking SPEG to AF involves its regulation of calcium homeostasis; by interacting with SERCA2a and promoting calcium reuptake into the sarcoplasmic reticulum, SPEG influences action potential duration and the propensity for arrhythmia. Abnormal SPEG expression may contribute to both the initiation and maintenance of AF by affecting calcium handling and promoting atrial fibrosis. Several single nucleotide polymorphisms (SNPs) in SPEG, including rs576016632, have been identified as rare variants associated with AF, though the contribution of specific variants may vary across populations. Therapeutically, SPEG represents a potential target for the treatment of heart failure and arrhythmia. Understanding the precise molecular mechanisms by which SPEG regulates SERCA2a and junctophilin-2 phosphorylation may facilitate the development of small molecule modulators of SPEG kinase activity. For patients with SPEG-associated DCM, standard heart failure management with beta-blockers, angiotensin II receptor blockers, and phosphodiesterase inhibitors is currently the mainstay of treatment, though progression to end-stage heart failure and the need for cardiac transplantation remains common. Gene therapy approaches to restore SPEG expression or function are theoretically promising but remain at the preclinical stage. Given the restricted expression pattern of SPEG in striated muscle, it represents an attractive target for muscle-specific therapeutic interventions with potentially limited off-target effects.

Alternate Names for SPEG

SPEG; SPEG complex locus; BPEG; APEG1; APEG-1; SPEGbeta; SPEGalpha; striated muscle preferentially expressed protein kinase; aortic preferentially expressed gene 1; aortic preferentially expressed protein 1